ClinicalTrials.gg
CompletedNCT01525173Updated Dec 4, 2013Results posted

A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

A Phase 4 interventional study of 0.1% brimonidine tartrate ophthalmic solution and 0.01% bimatoprost ophthalmic solution in Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-04.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing brimonidine in Glaucoma — 1 open to participants now, 1 under way, none of them phase 3. brimonidine · Glaucoma.

Enrollment
6th of 21
137 · median 56
Started
2012
with 1 other
Phase 4
10 of 23
1 open now
Registered
18th of 23
by date
Lead sponsor
5 of 23
Allergan

Among the 23 studies testing brimonidine in Glaucoma, this one is the 6th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2012, is one of 10 in phase 4, and was the 18th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

1 of the 23 studies testing brimonidine in Glaucoma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing brimonidine in Glaucoma, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P) in combination in patients previously treated with latanoprost 0.005% ophthalmic solution monotherapy who require additional intraocular pressure (IOP) lowering medication.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ocular hypertension or glaucoma in at least 1 eye
  • Visual acuity of 20/100 or better in both eyes

Exclusion criteria

Exclusion Criteria:

  • Corneal refractive laser surgery (LASIK, LASEK, PRK, RK) in the study eye(s)
  • Intraocular or glaucoma surgery in the past 3 months
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
137 participants (actual)

Study arms

  • Active comparator
    ALPHAGAN® P and LUMIGAN®

    1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.1% brimonidine tartrate ophthalmic solution (ALPHAGAN® P) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.

    Drug: 0.1% brimonidine tartrate ophthalmic solution · Drug: 0.01% bimatoprost ophthalmic solution · Drug: latanoprost 0.005% ophthalmic solution

  • Active comparator
    LUMIGAN® Alone

    1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.2% hypromellose lubricant eye drops (used for masking purposes) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.

    Drug: 0.01% bimatoprost ophthalmic solution · Drug: 0.2% hypromellose lubricant eye drops · Drug: latanoprost 0.005% ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Diurnal Intraocular Pressure (IOP)

    IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the study eye, defined as the worse eye at Baseline. The mean diurnal IOP is the average of all the IOP measurements in the study eye taken at 8 AM, 10 AM and 4 PM at Baseline and at Week 12. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 12

07

Results

Posted Dec 4, 2013

Participant flow

Participant flow — Overall Study
MilestoneALPHAGAN® P and LUMIGAN®LUMIGAN® Alone
Started7067
Completed6362
Not completed75

Outcome measures

PrimaryChange From Baseline in Mean Diurnal Intraocular Pressure (IOP)

IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the study eye, defined as the worse eye at Baseline. The mean diurnal IOP is the average of all the IOP measurements in the study eye taken at 8 AM, 10 AM and 4 PM at Baseline and at Week 12. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · mm Hg
Change From Baseline in Mean Diurnal Intraocular Pressure (IOP)
mm HgALPHAGAN® P and LUMIGAN®LUMIGAN® Alone
Baseline22.3 ± 2.2222.2 ± 2.44
Change from Baseline at Week 12-4.7 ± 2.55-4.0 ± 3.23

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ALPHAGAN® P and LUMIGAN®—1/70 (1.4%)4/70 (5.7%)
LUMIGAN® Alone—2/67 (3%)0/67 (0%)
Most frequent serious events
Most frequent serious events
EventALPHAGAN® P and LUMIGAN®LUMIGAN® Alone
Prolonged hospitalization cardiac ischemiaCardiac disorders0/701/67
Exacerbation of depression disorderPsychiatric disorders0/701/67
Esophageal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/700/67
Most frequent other events
Most frequent other events
EventALPHAGAN® P and LUMIGAN®LUMIGAN® Alone
Ocular hyperemiaEye disorders4/700/67

Baseline characteristics

Age Continuous
Age Continuous(Years)ALPHAGAN® P and LUMIGAN®LUMIGAN® AloneTotal
Mean65.7 ± 11.8761.1 ± 13.9163.4 ± 13.06
Sex: Female, Male
Sex: Female, Male(Participants)ALPHAGAN® P and LUMIGAN®LUMIGAN® AloneTotal
Female313364
Male393473
08

Study locations

1 site
  • Deerfield Beach, Florida, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2012
First posted
Feb 2, 2012
Start
Jan 2012
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
Dec 4, 2013
Last update
Dec 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01525173
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Feb 2, 2012
Start date
Jan 2012
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Dec 4, 2013
Last update
Dec 4, 2013

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brimonidine · Hypromellose Derivatives

Start the discussion